Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study

摘要

Background To compare the long-term efficacy of ranibizumab versus bevacizumab for myopic choroidal neovascularization (CNV). Methods This was a retrospective, multicenter, comparative, non-randomized study of 64 consecutive patients with myopic CNV treated with ranibizumab (22 patients) or bevacizumab (42 patients). Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment. All the patients were followed for at least 12?months. Results BCVA (logarithm of the minimal angle of resolution) improved from 0.63?±?0.30 to 0.43?±?0.27, 0.41?±?0.37, 0.40?±?0.39, 0.39?±?0.43, and 0.39?±?0.42 at 1, 2, 3, 6, and 12?months after treatment in the ranibizumab group, and from 0.67?±?0.28 to 0.52?±?0.31, 0.49?±?0.31, 0.47?±?0.31, 0.42?±?0.32, and 0.46?±?0.43 in the bevacizumab group (all P?P? Conclusions This study showed a similar functional and anatomical improvement after treatment of ranibizumab and bevacizumab for myopic CNV over a 12-month follow-up period.